Hyperuricemic nephropathy, familial juvenile type 3

disease
On this page

Also known as HNFJ3hyperuricemic nephropathy, familial juvenile, 3

Summary

Hyperuricemic nephropathy, familial juvenile type 3 (MONDO:0013643) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namehyperuricemic nephropathy, familial juvenile type 3
Mondo IDMONDO:0013643
OMIM614227
UMLSC3280216
MedGen481846
Is cancer (heuristic)no

Also known as: HNFJ3 · hyperuricemic nephropathy, familial juvenile, 3

Data availability: 2 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inherited kidney disorder › familial juvenile hyperuricemic nephropathyhyperuricemic nephropathy, familial juvenile type 3

Related subtypes (5): familial juvenile hyperuricemic nephropathy type 1, familial juvenile hyperuricemic nephropathy type 2, hyperuricemic nephropathy, familial juvenile type 4, tubulointerstitial kidney disease, autosomal dominant, 2, tubulointerstitial kidney disease, autosomal dominant 6

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 pathogenic, 1 conflicting classifications of pathogenicity

ClinVarVariant (HGVS)GeneClassificationReview
446150NM_000458.4(HNF1B):c.230_233del (p.Asp77fs)HNF1BPathogeniccriteria provided, multiple submitters, no conflicts
636234NM_000458.4(HNF1B):c.458A>G (p.His153Arg)HNF1BConflicting classifications of pathogenicitycriteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
HNF1BOrphanet:1309Medullary sponge kidney
HNF1BOrphanet:1331Familial prostate cancer
HNF1BOrphanet:2578Mayer-Rokitansky-Küster-Hauser syndrome type 2
HNF1BOrphanet:26126517q12 microdeletion syndrome
HNF1BOrphanet:93111HNF1B-related autosomal dominant tubulointerstitial kidney disease
HNF1BOrphanet:93172Renal dysplasia, unilateral
HNF1BOrphanet:93173Renal dysplasia, bilateral
HNF1BOrphanet:97363Unilateral multicystic dysplastic kidney
HNF1BOrphanet:97364Bilateral multicystic dysplastic kidney

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
HNF1BHGNC:11630ENSG00000275410P35680Hepatocyte nuclear factor 1-betaclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
HNF1BHepatocyte nuclear factor 1-betaTranscription factor that binds to the inverted palindrome 5’-GTTAATNATTAAC-3'.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor18.3×0.121

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
HNF1BTranscription factornoHD, HNF1b_C, HNF-1_N

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
adult mammalian kidney1
kidney1
metanephros cortex1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
HNF1B74broadmarkermetanephros cortex, adult mammalian kidney, kidney

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
HNF1B1,660

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
HNF1BP356803

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Regulation of gene expression in early pancreatic precursor cells11427.5×0.002HNF1B
Nephron development1878.5×0.002HNF1B
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells1713.8×0.002HNF1B
Developmental Lineage of Multipotent Pancreatic Progenitor Cells1601.0×0.002HNF1B
Developmental Lineage of Pancreatic Acinar Cells1300.5×0.004HNF1B
Developmental Lineage of Pancreatic Ductal Cells1228.4×0.004HNF1B

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
regulation of pronephros size116852.0×4e-04HNF1B
pronephric nephron tubule development116852.0×4e-04HNF1B
ureteric bud elongation116852.0×4e-04HNF1B
obsolete negative regulation of mesenchymal cell apoptotic process involved in mesonephric nephron morphogenesis116852.0×4e-04HNF1B
mesenchymal cell apoptotic process involved in metanephros development116852.0×4e-04HNF1B
hepatoblast differentiation18426.0×5e-04HNF1B
mesonephric duct formation18426.0×5e-04HNF1B
regulation of branch elongation involved in ureteric bud branching15617.3×6e-04HNF1B
negative regulation of mesenchymal cell apoptotic process involved in metanephros development15617.3×6e-04HNF1B
endodermal cell fate specification12808.7×0.001HNF1B
inner cell mass cell differentiation12808.7×0.001HNF1B
pronephros development12407.4×0.001HNF1B
genitalia development11685.2×0.001HNF1B
hindbrain development11123.5×0.002HNF1B
endocrine pancreas development1936.2×0.002HNF1B
embryonic digestive tract morphogenesis1936.2×0.002HNF1B
regulation of Wnt signaling pathway1887.0×0.002HNF1B
branching morphogenesis of an epithelial tube1732.7×0.002HNF1B
pancreas development1674.1×0.002HNF1B
insulin secretion1432.1×0.004HNF1B
epithelial cell proliferation1312.1×0.005HNF1B
positive regulation of transcription initiation by RNA polymerase II1271.8×0.005HNF1B
response to glucose1255.3×0.005HNF1B
anterior/posterior pattern specification1181.2×0.007HNF1B
Notch signaling pathway1141.6×0.008HNF1B
kidney development1140.4×0.008HNF1B
gene expression179.9×0.014HNF1B
positive regulation of gene expression138.7×0.029HNF1B
positive regulation of DNA-templated transcription127.9×0.038HNF1B
negative regulation of transcription by RNA polymerase II117.7×0.058HNF1B

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
HNF1B00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1HNF1B

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
HNF1B0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.